Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study

2021 ◽  
Vol 157 ◽  
pp. 106-113 ◽  
Author(s):  
Marie Louise Holm Milo ◽  
Lise Bech Jellesmark Thorsen ◽  
Søren Paaske Johnsen ◽  
Kirsten Melgaard Nielsen ◽  
Jan Brink Valentin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cancer Patients ◽  
Adjuvant Radiotherapy ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Artery Disease

scholarly journals Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman

2020 ◽  
pp. 107815522091988
Author(s):  
Doaa Abd Alghafar ◽  
Ibrahim Younos ◽  
Khalid Al Baimani ◽  
Dawood Al-Salhi ◽  
Adil Al-Riyami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Ejection Fraction ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Artery Disease ◽  
Positive Breast Cancer

Trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), is used to treat breast cancers harboring amplification of the HER2 locus. Cardiotoxicity is a common side effect of trastuzumab that leads to discontinuation of treatment in a significant proportion of cancer patients. In our retrospective study, we evaluate the prevalence and identify the risk factors for cardiotoxicity associated with trastuzumab in HER2-positive breast cancer patients attending to Sultan Qaboos University Hospital between 10/2012 and 10/2017. Using patient records, we collected patients’ characteristics (age, menopausal status, lymph nodal status, distant metastasis at presentation, grade of tumor, comorbidities (diabetes mellitus, hypertension, coronary artery disease diseases)), chemotherapy received and total dose of trastuzumab as well as cardiotoxicity (including timing). Cardiotoxicity was defined based on the ejection fraction dropping by 10% of the original value or a drop in the ejection fraction below the normal value. Among the 146 patients included in the study, 35 showed trastuzumab-induced cardiotoxicity (24%). Twenty-nine (83%) of those patients stopped trastuzumab temporarily. Risk of trastuzumab-induced cardiotoxicity was not altered by common cardiac risk factors such as history of coronary artery disease, hypertension and diabetes. Previous anthracyclines therapy exposure increased the risk of trastuzumab-induced cardiotoxicity significantly ( p =  0.009). None of the other covariates influenced the incidence of trastuzumab-induced cardiotoxicity, which may be related to the relatively small sample size. Further studies are warranted to establish ways to predict, prevent, and treat trastuzumab-induced cardiotoxicity to provide patients with maximal therapeutic benefit.

CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA

1995 ◽  
Vol 10 (2) ◽  
pp. 94-99 ◽  
Author(s):  
M. Torres ◽  
C. Pacheco ◽  
A. Valverde ◽  
A.C. Rebollo ◽  
A. Moral ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Statistical Analysis ◽  
Cancer Patients ◽  
Blood Donors ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Benign Diseases ◽  
Ca 15.3 ◽  
Cancer Group ◽  
Breast Cancer Group

The levels of CA 549 and SP2 were measured in 430 subjects: 100 healthy blood donors, 130 patients with benign diseases and 200 postoperative breast cancer patients. In the latter group, the serum levels of CA 15.3, CEA and TPA were also measured. The Kolmogorov-Smirnov, Mann Whitney and McNemar tests were used for statistical analysis. The upper normal limits were established on the basis of the values obtained in the healthy blood donors group, the benign diseases group and R.O.C. analysis of the breast cancer group. They were: CA 549 = 13 U/ml, SP2 = 14 U/ml, CA 15.3 = 35 U/ml, CEA = 5 ng/ml and TPA = 110 U/ml. The sensitivity, specificity and accuracy in the breast cancer group were, respectively: CA 549 = 78.1%, 97.1% and 88%; SP2 = 21.9%, 90.4% and 57.5%; CEA = 66.7%, 95.2% and 81.5%; CA 15.3 = 80.2%, 98.1% and 89.5%, and TPA = 73.9%, 78.8% and 76.5%. Statistical analysis showed significant differences only between CA 15.3, the marker which gave the best results, and SP2 (p<0.001). There were no significant differences with the association of two or three tumor markers.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 515-515
Author(s):  
Frederic Amant ◽  
Valentina Nekljudova ◽  
Charlotte Maggen ◽  
Fenja Seither ◽  
Patrick Neven ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Breast Cancer Patients ◽  
Cancer Data ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Grade 3

515 Background: Overall a diagnosis of breast cancer during pregnancy (BCP) appears not to impact maternal prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics with respect to the distribution, metabolism and excretion of drugs may lead to reduced chemotherapy concentration in pregnant patients. This cohort study was designed to focus on the maternal prognosis of BCP patients that receive chemotherapy during pregnancy. Methods: The outcome of BCP patients treated with chemotherapy during pregnancy was compared to non-pregnant breast cancer patients treated with chemotherapy, diagnosed after 2000, excluding postpartum diagnosis and with an age limit of 45 years. The data was registered by two multicentric registries (the International Network of Cancer, Infertility and Pregnancy and the German Breast Cancer Group) that collect both retro-and prospectively breast cancer data. Cox proportional hazards regression was used to compare disease-free (DFS) and overall survival (OS) between both groups, adjusting for age, stage, grade, hormone receptor status, human epidermal growth factor 2 status and histology, weighted by propensity scoring in order to account for the differences in baseline characteristics between pregnant patients and controls. Results: In total, 662 pregnant and 2081 non-pregnant patients, were eligible for analysis. Median age at diagnosis was 34 (range 22-47) years for pregnant and 38 (range 19-45) years for non-pregnant patients. Pregnant patients were more likely to have stage II breast cancer (60.1% vs 56.1%, p = 0.035), grade 3 tumors (74.0% vs 62.2%, p < 0.001), hormone receptor-negative tumors (48.4% vs 34.0%, p < 0.001) or triple-negative breast cancer (38.9% vs 26.9%, p < 0.001). Median follow-up was 66 months. DFS and OS were comparable for pregnant and non-pregnant patients (DFS: HR 1.02, 95%CI 0.82-1.27, p = 0.83; OS: HR 1.08, 95% CI 0.81-1.45, p = 0.59). A subgroup analysis of 339 women that received more than 60% of chemotherapy during pregnancy (cut-off at median) revealed a comparable survival compared to non-pregnant women (DFS: HR 0.81, 95%CI 0.62-1.06, p = 0.13; OS: HR 0.85 95% CI 0.58-1.23, p = 0.39). Conclusions: Pregnancy-induced alternations in chemotherapy concentration do not seem to affect maternal prognosis in breast cancer patients. These results support initiation of chemotherapy for BCP where indicated for oncological reasons.

scholarly journals Early detection of Breast Cancer by Tumor Marker CA15.3, CA27.29 and relationship with P53 and Vitamin D

2014 ◽  
Vol 8 (1) ◽  
pp. 59-65
Author(s):  
Ryaidh Sh. Al-Hussain ◽  
Eman M. Kathaem ◽  
Luay N. Baker ◽  
Saeed H. Assi ◽  
Saad S. Abdulbaqi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Tumor Marker ◽  
Cancer Patients ◽  
The Body ◽  
Breast Cancer Patients ◽  
Cancer Group ◽  
Significant Difference ◽  
Breast Cancer Group ◽  
And Control

Breast cancer is the second most frequent cancer of women. Tumor markers are substances that can be found in the body when cancer is present. The classic tumor marker is a protein that can be found in the blood in increased levels when the cancer is present.The present study have been investigated the levels of cancer antigen CA15.3, CA27.29, P53 and Vitamin D in women with breast cancer, aged were 30-75 years old, they divided into four groups, each group composed of 50 women included breast cancer patients aged 30-59 year, breast cancer patients aged 60-75 years, milking nodules groups 30-60 year and control groups. This study showed significant P<0.05 increasing in the level of CA15.3, CA27.29 and P53 concentration in milking nodules and both breast cancer groups, also showed significant P<0.05 decreasing in vitamin D concentration in milking group and breast cancer group and significant difference in serum Ca concentration.

Sign in / Sign up

Export Citation Format

Share Document